Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AMICUS THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for AMICUS THERAPEUTICS, INC.

FOLD

AMICUS THERAPEUTICS, INC.

About AMICUS THERAPEUTICS, INC.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to developing innovative therapies for rare diseases, particularly Fabry and Pompe diseases. Its key products include Galafold®, the first oral treatment for Fabry disease, and Pombiliti® + Opfolda®, a dual therapy for Pompe disease. With a focus on precision medicine, Amicus aims to expand its market presence and enhance patient outcomes through ongoing research and strategic partnerships.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from AMICUS THERAPEUTICS, INC.

1
1
AMICUS THERAPEUTICS, INC. Amicus Therapeutics Reports Revenue Growth to $634.2 Million, Plans Merger with BioMarin

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
AMICUS THERAPEUTICS, INC. Amicus Therapeutics Reports 19.4% Increase in Quarterly Net Product Sales

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
AMICUS THERAPEUTICS, INC. Amicus Therapeutics Reports 22.1% Revenue Growth in Q2 2025, Net Loss Increases

Via official filing (AI summary) | 11 months ago | 0 comments

4
1
AMICUS THERAPEUTICS, INC. Amicus Therapeutics Reports 13.4% Increase in Net Product Sales for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
AMICUS THERAPEUTICS, INC. Amicus Therapeutics Reports $528.3 Million in Net Product Sales for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
AMICUS THERAPEUTICS, INC. Amicus Therapeutics Reports Strong Financial Growth, Net Product Sales Reach $141.5M in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments